$10,000 of DIEBOLD NIXDORF lobbying was just disclosed, from Q2 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"H.R.1138 - Payment Choice Act of 2025 This bill requires retail businesses to accept cash as a form of payment for on-site sales of $500 or less, and it prohibits them from charging cash- paying customers a higher price compared to customers not paying with cash. Businesses covered by this bill are those engaged in the business of selling or offering goods or services at retail to the public that accept in-person payments at a physical location. The bill provides for enforcement through preventative relief, damages, and civil penalties. H.R.1138 - Payment Choice Act of 2025 This bill requires retail businesses to accept cash as a form of payment for on-site sales of $500 or less, and it prohibits them from charging cash- paying customers a higher price compared to customers not paying with cash. Businesses covered by this bill are those engaged in the business of selling or offering goods or services at retail to the public that accept in-person payments at a physical location. The bill provides for enforcement through preventative relief, damages, and civil penalties. H.R.1138 - Payment Choice Act of 2025 This bill requires retail businesses to accept cash as a form of payment for on-site sales of $500 or less, and it prohibits them from charging cash- paying customers a higher price compared to customers not paying with cash. Businesses covered by this bill are those engaged in the business of selling or offering goods or services at retail to the public that accept in-person payments at a physical location. The bill provides for enforcement through preventative relief, damages, and civil penalties."
You can find more data on corporate lobbying on Quiver Quantitative.
DBD Insider Trading Activity
DBD insiders have traded $DBD stock on the open market 4 times in the past 6 months. Of those trades, 1 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $DBD stock by insiders over the last 6 months:
- WORLD INVESTORS CAPITAL sold 19,842 shares for an estimated $866,103
- EMANUEL R PEARLMAN has made 0 purchases and 2 sales selling 2,000 shares for an estimated $87,360.
- FRANK TOBIAS BAUR (EVP of Operational Excellence) purchased 700 shares for an estimated $32,284
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
DBD Hedge Fund Activity
We have seen 61 institutional investors add shares of DBD stock to their portfolio, and 65 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BEACH POINT CAPITAL MANAGEMENT LP removed 317,399 shares (-16.8%) from their portfolio in Q2 2025, for an estimated $17,583,904
- NEW VERNON CAPITAL HOLDINGS II LLC added 244,351 shares (+inf%) to their portfolio in Q1 2025, for an estimated $10,683,025
- GLENDON CAPITAL MANAGEMENT LP added 180,232 shares (+13.7%) to their portfolio in Q1 2025, for an estimated $7,879,743
- UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH added 153,600 shares (+inf%) to their portfolio in Q1 2025, for an estimated $6,715,392
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC added 140,290 shares (+9.5%) to their portfolio in Q2 2025, for an estimated $7,772,066
- DIMENSIONAL FUND ADVISORS LP added 114,486 shares (+18.2%) to their portfolio in Q1 2025, for an estimated $5,005,327
- SKYLANDS CAPITAL, LLC added 103,975 shares (+23.3%) to their portfolio in Q1 2025, for an estimated $4,545,787
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
DBD Analyst Ratings
Wall Street analysts have issued reports on $DBD in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- DA Davidson issued a "Buy" rating on 02/27/2025
To track analyst ratings and price targets for DBD, check out Quiver Quantitative's $DBD forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
